Stroke prevention: managing modifiable risk factors.

Stroke Res Treat · 2012 · PMC3504482 · PMID 23213626

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the stroke subgroup, telmisartan 80 mg showed a trend toward reducing recurrent stroke versus ramipril 10 mg (HR 0.91; 95% CI, 0.79–1.05).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.